Copanlisib for Treatment of B-Cell Malignancies: The Development of a PI3K Inhibitor With Considerable Differences to Idelalisib
Drug Design, Development and Therapy - New Zealand
doi 10.2147/dddt.s142406
Full Text
Open PDFAbstract
Available in full text
Date
August 1, 2018
Authors
Publisher
Informa UK Limited